Cost Effectiveness of Interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-α antagonist therapy

Molecular Diagnosis and Therapy

Volumn 14, Issue 6, 2010, Pages 367-373

  Kowada, Akiko ^a  

^a Bunkyo City Public Health Center   (Japan)

Author keywords

Cost effectiveness; Descriptors; Diagnostic Tests; Rheumatoid arthritis; Tuberculosis; Tumour necrosis factor inhibitors, general

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; ASSAY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SCREENING; TUBERCULOSIS;

ADULT; ARTHRITIS, RHEUMATOID; HUMANS; INTERFERON-GAMMA; JAPAN; LATENT TUBERCULOSIS; MASS SCREENING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

MYCOBACTERIUM BOVIS BCG;

EID: 79551539371     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.2165/11586190-000000000-00000     Document Type: Article

References (32)

1. Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009 Nov; 13 (11): 1427-32
2. Maeda T, Banno S, Maeda S, et al. Usefulness and limitations of Quanti- FERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol 2010 Feb; 20 (1): 18-23
3. Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008 Jun 15; 59 (6): 800-6
4. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur JClin Microbiol Infect Dis 2008 Oct; 27 (10): 907-13
5. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008 May; 35 (5): 776-81
6. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007 Oct; 27 (12): 1143-8
7. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-94
8. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008 Dec; 8 (2): 147-52
9. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007 Jan; 11 (1): 16-26
10. Ministry of Health, Labor and Welfare. Epidemiology of tuberculosis in Japan. Tokyo: Ministry of Health, Labor and Welfare, 2008
11. Kowada A, Takahashi O, Shimbo T, et al. Cost effectiveness of interferongamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 2008; 12 (4): 235-51
12. de Perio MA, Tsevat J, Roselle GA, et al. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009 Jan 26; 169 (2): 179-87
13. Hardy AB, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010 Feb; 65 (2): 178-80
14. Mazurek M, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010 Jun 25; 59 (RR-5): 1-25
15. Japanese College of Rheumatology. Adarimumabu use guideline to articular rheumatism 2008.7.2 [in Japanese; online]. Available from URL: http:// www.ryumachi-jp.com/info/guideline-ADA.pdf [Accessed 2010 Jul 19]
16. Saag K, Teng G, Patkar N. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rhematoid arthritis. Arthritis Rheum 2008; 59 (6): 762-84
17. Kowada A, Deshpande GA, Takahashi O, et al. Cost effectiveness of interferongamma release assay versus chest x-ray for tuberculosis screening of BCGvaccinated elderly populations. Mol Diagn Ther 2010; 14 (4): 229-36
18. Diel R, Schaberg T, Loddenkemper R, et al. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med 2009 Dec; 103 (12): 1838-53
19. Ministry of Health, Labor and Welfare. Basic survey on wage structure in Japan [in Japanese]. Tokyo: Ministry of Health, Labor and Welfare, 2008
20. Ministry of Health, Labor and Welfare. Life tables in Japan, 2008 [in Japanese; online]. Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/ jin kou/geppo/nengai09/kekka3.html [Accessed 2010 Jul 19]
21. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146 (5): 340-54
22. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137 (4): 952-68
23. Tuberculosis Research Committee (Ryoken). Relapse rate of tuberculosis treated with standard regimen of chemotherapy [in Japanese]. Kekkaku 2009 Sep; 84 (9): 617-25
24. Horsburgh Jr CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350 (20): 2060-7
25. Yoshiyama T. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings. Kekkaku 2000; 75 (11): 629-41
26. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128 (1): 116-23
27. Igakutsushinsya. Medical insurance reimbursement table in Japan [in Japanese]. Tokyo: Igakutsushinsya, 2008 [online]. Available from URL: http://igakutushin.co.jp/index1.php?contenturl=page1.php?sid=299 [Accessed 2009 Nov 22]
28. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005; 26 (3): 465-73
29. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149 (3): 177-84
30. Diel R, Loddenkemper R, Nienhaus A. Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis - a meta-analysis. Chest 2010; 137 (4): 952-68
31. Bank of Mitsubishi UFJ. Exchange quotations 2009 [online]. Available from URL: http://www.murc.jp/fx/year-average.php [Accessed 2010 Nov 22]
32. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 2007 Jun; 4 (6): e208